Market Research Logo

Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015

Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2015’, provides an overview of the Non-Alcoholic Steatohepatitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Non-Alcoholic Steatohepatitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Non-Alcoholic Steatohepatitis Overview
Therapeutics Development
Pipeline Products for Non-Alcoholic Steatohepatitis - Overview
Pipeline Products for Non-Alcoholic Steatohepatitis - Comparative Analysis
Non-Alcoholic Steatohepatitis - Therapeutics under Development by Companies
Non-Alcoholic Steatohepatitis - Therapeutics under Investigation by Universities/Institutes
Non-Alcoholic Steatohepatitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Non-Alcoholic Steatohepatitis - Products under Development by Companies
Non-Alcoholic Steatohepatitis - Products under Investigation by Universities/Institutes
Non-Alcoholic Steatohepatitis - Companies Involved in Therapeutics Development
AlbireoPharma
Aquinox Pharmaceuticals Inc.
Ardelyx, Inc.
Arisaph Pharmaceuticals, Inc.
BiOrion Technologies B.V.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cardax Pharmaceuticals, Inc.
Cerenis Therapeutics Holding SA
Conatus Pharmaceuticals Inc.
Connexios Life Sciences Pvt. Ltd.
Daiichi Sankyo Company, Limited
Dr. Falk Pharma GmbH
DURECT Corporation
Dynavax Technologies Corporation
Enanta Pharmaceuticals, Inc.
Exicure, Inc.
Galectin Therapeutics, Inc.
Galmed International Ltd.
Genfit SA
GenKyoTex S.A.
Gilead Sciences, Inc.
iCo Therapeutics Inc.
Immuron Limited
Intercept Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc.
Jenrin Discovery, Inc.
Kissei Pharmaceutical Co., Ltd.
Kyorin Pharmaceutical Co., Ltd.
Merck & Co., Inc.
Mochida Pharmaceutical Co., Ltd.
NGM Biopharmaceuticals, Inc.
Nimbus Therapeutics, LLC
Nippon Chemiphar Co., Ltd.
Novartis AG
Novo Nordisk A/S
ProMetic Life Sciences Inc.
Protalix BioTherapeutics, Inc.
Regulus Therapeutics Inc.
RuiYi Inc.
Shire Plc
Stelic Institute & Co.
Therapix Biosciences Ltd
Tobira Therapeutics, Inc.
Vascular Biogenics Ltd.
Verva Pharmaceuticals Limited
Viking Therapeutics, Inc.
Virobay Inc.
Zafgen Inc.
Zydus Cadila Healthcare Limited
Non-Alcoholic Steatohepatitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(leucine + metformin + sildenafil) - Drug Profile
A-4250 - Drug Profile
AM-0010 - Drug Profile
AQX-1125 - Drug Profile
Aramchol - Drug Profile
ARI-3037MO - Drug Profile
bertilimumab - Drug Profile
BMS-986036 - Drug Profile
BOT-191 - Drug Profile
CDX-085 - Drug Profile
cenicriviroc mesylate - Drug Profile
CER-209 - Drug Profile
CNX-014 - Drug Profile
CNX-023 - Drug Profile
CNX-024 - Drug Profile
CNX-025 - Drug Profile
DUR-928 - Drug Profile
DV-1179 - Drug Profile
elafibranor - Drug Profile
emricasan - Drug Profile
etanercept biosimilar - Drug Profile
GKT-831 - Drug Profile
GR-MD-02 - Drug Profile
icosapent ethyl - Drug Profile
IMM-124E - Drug Profile
ISIS-DGAT2Rx - Drug Profile
JD-5037 - Drug Profile
JKB-119 - Drug Profile
JKB-121 - Drug Profile
liraglutide (recombinant) - Drug Profile
LJN-452 - Drug Profile
MAT-8800 - Drug Profile
methazolamide - Drug Profile
MGL-3196 - Drug Profile
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile
NC-101 - Drug Profile
NC-2400 - Drug Profile
ND-630 - Drug Profile
ND-654 - Drug Profile
NDI-010976 - Drug Profile
NGM-282 - Drug Profile
norursodeoxycholic acid - Drug Profile
NP-201 - Drug Profile
obeticholic acid - Drug Profile
Oligonucleotides for Non-Alcoholic Steatohepatitis - Drug Profile
PBI-4050 - Drug Profile
pentamidine isethionate - Drug Profile
Px-102 - Drug Profile
Px-103 - Drug Profile
PXS-4728A - Drug Profile
PZ-235 - Drug Profile
RDX-009 - Drug Profile
remogliflozin etabonate - Drug Profile
RG-125 - Drug Profile
RYI-018 - Drug Profile
saroglitazar - Drug Profile
SDP-051 - Drug Profile
selonsertib - Drug Profile
simtuzumab - Drug Profile
Small Molecule for Non-Alcoholic Steatohepatitis - Drug Profile
Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile
Small Molecules to Agonize Farnesoid X Receptor for Non-alcoholic Steatohepatitis and Primary Biliary Cirrhosis - Drug Profile
solithromycin - Drug Profile
SR-9238 - Drug Profile
STNM-09 - Drug Profile
TGFTX-3 Program - Drug Profile
tipelukast - Drug Profile
TRX-318 - Drug Profile
VB-201 - Drug Profile
VBY-376 - Drug Profile
VK-0214 - Drug Profile
VK-2809 - Drug Profile
volixibat potassium - Drug Profile
VVP-100-X - Drug Profile
ZGN-839 - Drug Profile
Non-Alcoholic Steatohepatitis - Recent Pipeline Updates
Non-Alcoholic Steatohepatitis - Dormant Projects
Non-Alcoholic Steatohepatitis - Discontinued Products
Non-Alcoholic Steatohepatitis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Non-Alcoholic Steatohepatitis, H2 2015
Number of Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by AlbireoPharma, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Aquinox Pharmaceuticals Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Ardelyx, Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by BiOrion Technologies B.V., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Bristol-Myers Squibb Company, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Cerenis Therapeutics Holding SA, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Conatus Pharmaceuticals Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Dr. Falk Pharma GmbH, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by DURECT Corporation, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Dynavax Technologies Corporation, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Enanta Pharmaceuticals, Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Exicure, Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Galectin Therapeutics, Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Galmed International Ltd., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Genfit SA, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by GenKyoTex S.A., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Gilead Sciences, Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by iCo Therapeutics Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Immuron Limited, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Isis Pharmaceuticals, Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Jenrin Discovery, Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Merck & Co., Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Mochida Pharmaceutical Co., Ltd., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by NGM Biopharmaceuticals, Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Nimbus Therapeutics, LLC, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Nippon Chemiphar Co., Ltd., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Novartis AG, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Novo Nordisk A/S, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by ProMetic Life Sciences Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Protalix BioTherapeutics, Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Regulus Therapeutics Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by RuiYi Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Shire Plc, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Stelic Institute & Co., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Therapix Biosciences Ltd, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Tobira Therapeutics, Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Vascular Biogenics Ltd., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Verva Pharmaceuticals Limited, H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Viking Therapeutics, Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Virobay Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Zafgen Inc., H2 2015
Non-Alcoholic Steatohepatitis - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Non-Alcoholic Steatohepatitis Therapeutics - Recent Pipeline Updates, H2 2015
Non-Alcoholic Steatohepatitis - Dormant Projects, H2 2015
Non-Alcoholic Steatohepatitis - Dormant Projects (Contd..1), H2 2015
Non-Alcoholic Steatohepatitis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Non-Alcoholic Steatohepatitis, H2 2015
Number of Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report